Transcriptomics-based drug repositioning in a neurocysticercosis rat model identifies putative therapeutic candidates reported to mitigate neuroinflammation and neurodegeneration
Using transcriptomic profiling of a rat model to analyze molecular changes during neurocysticercosis infection and treatment, researchers identified 30 candidate drugs for repurposing, including five known to mitigate neuroinflammation and neurodegeneration, thereby establishing a molecular rationale for new therapeutic strategies against this disease.